Nonsmall cell lung carcinoma (NSCLC) accounts for 80 % of lung cancers. The most prevalent subtypes of NSCLC are adenocarcinoma (ADC) and squamous cell carcinoma (SCC), which combined account for approximately 90%. Ten resected NSCLC patient tumors (5 ADC and 5 SCC) were directly introduced into severely immune deficient (NOD-SCID) mice, and the resulting xenograft tumors were analyzed by standard histology and immunohistochemistry (IHC) and by proteomics profiling. Mass spectrometry (MS) methods involving 1- and 2-dimensional LC-MS/MS, andmultiplexed selective reactionmonitoring (SRM, or MRM), were applied to identify and quantify the xenograft proteomes. Hierarchical clustering of protein profiles distinguished between the ADC and SCC sub...
Patients with head-and-neck cancer can develop both lung metastasis and primary lung cancer during t...
Patients with head‐and‐neck cancer can develop both lung metastasis and primary lung cancer during t...
Despite major advancements in lung cancer treatment, long-term survival is still rare and a deeper u...
Lung cancer is one of the most common cancers worldwide, and is the top cause of cancer-related deat...
Non-small cell lung cancer (NSCLC) cell lines are widely used model systems to study molecular aspec...
Abstract Background Non-small cell lung carcinoma (NSCLC) remains the leading cause of cancer deaths...
Lung cancer is the leading cause of preventable death globally and is broadly classified into adenoc...
UnlabelledDespite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC)...
BACKGROUND: A gel-free proteomic approach was utilized to perform in-depth tissue protein profiling ...
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. The high mortalit...
Advances in proteomic analysis of human samples are driving critical aspects of biomarker discovery ...
Potential markers for progression of pulmonary squamous cell carcinoma (SCC) were identified by exam...
Patients with head‐and‐neck cancer can develop both lung metastasis and primary lung cancer during t...
The most widely used cancer animal model is the human-murine tumor xenograft. Unbiased molecular dis...
Potential markers for progression of pulmonary squamous cell carcinoma (SCC) were identified by exam...
Patients with head-and-neck cancer can develop both lung metastasis and primary lung cancer during t...
Patients with head‐and‐neck cancer can develop both lung metastasis and primary lung cancer during t...
Despite major advancements in lung cancer treatment, long-term survival is still rare and a deeper u...
Lung cancer is one of the most common cancers worldwide, and is the top cause of cancer-related deat...
Non-small cell lung cancer (NSCLC) cell lines are widely used model systems to study molecular aspec...
Abstract Background Non-small cell lung carcinoma (NSCLC) remains the leading cause of cancer deaths...
Lung cancer is the leading cause of preventable death globally and is broadly classified into adenoc...
UnlabelledDespite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC)...
BACKGROUND: A gel-free proteomic approach was utilized to perform in-depth tissue protein profiling ...
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. The high mortalit...
Advances in proteomic analysis of human samples are driving critical aspects of biomarker discovery ...
Potential markers for progression of pulmonary squamous cell carcinoma (SCC) were identified by exam...
Patients with head‐and‐neck cancer can develop both lung metastasis and primary lung cancer during t...
The most widely used cancer animal model is the human-murine tumor xenograft. Unbiased molecular dis...
Potential markers for progression of pulmonary squamous cell carcinoma (SCC) were identified by exam...
Patients with head-and-neck cancer can develop both lung metastasis and primary lung cancer during t...
Patients with head‐and‐neck cancer can develop both lung metastasis and primary lung cancer during t...
Despite major advancements in lung cancer treatment, long-term survival is still rare and a deeper u...